(Q37833642)

24 August 2017

1 reference

title

Threonine peptidases as drug targets against malaria (English)

1 reference

24 August 2017

0 references

2

Benjamin Mordmüller

1 reference

24 August 2017

Serena Tschan

1

1 reference

24 August 2017

Jürgen F J Kun

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Expert Opinion on Therapeutic Targets

24 August 2017

published in

1 reference

24 August 2017

volume

15

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

365-378

1 reference

Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Artemisinin-resistant malaria in Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Artemisinin Resistance in Plasmodium falciparum Malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Malarial parasites vs. antimalarials: never-ending rumble in the jungle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Emerging principles in protease-based drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

The role of Plasmodium falciparum food vacuole plasmepsins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

An aspartyl protease directs malaria effector proteins to the host cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

A calpain unique to alveolates is essential in Plasmodium falciparum and its knockdown reveals an involvement in pre-S-phase development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Evidence for a common role for the serine-type Plasmodium falciparum serine repeat antigen proteases: implications for vaccine and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

A comprehensive view on proteasomal sequences: implications for the evolution of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Eubacterial HslV and HslU subunits homologs in primordial eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

The regulatory particle of the Saccharomyces cerevisiae proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

The ubiquitin system for protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

The ubiquitin-proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

The ubiquitin system, disease, and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Plasmodium falciparum: the fungal metabolite gliotoxin inhibits proteasome proteolytic activity and exerts a plasmodicidal effect on P. falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Marine actinomycetes: a new source of compounds against the human malaria parasite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Gliotoxin and related epipolythiodioxopiperazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Proteasome inhibition in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

HslV-HslU: A novel ATP-dependent protease complex in Escherichia coli related to the eukaryotic proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Molecular machines for protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Mitochondrial localization of the threonine peptidase PfHslV, a ClpQ ortholog in Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Overexpression of the hslVU operon suppresses SOS-mediated inhibition of cell division in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Synergistic roles of HslVU and other ATP-dependent proteases in controlling in vivo turnover of sigma32 and abnormal proteins in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Identification of a bacterial-like HslVU protease in the mitochondria of Trypanosoma brucei and its role in mitochondrial DNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Multiple sequence alignment with the Clustal series of programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Plasmodia express two threonine-peptidase complexes during asexual development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

Bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555399

10.1517/14728222.2011.555399

21 January 2018

Identifiers

DOI

1 reference

release_ztad74lyqvgfzgdmyee5f7rjse

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ztad74lyqvgfzgdmyee5f7rjse

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference